<DOC>
	<DOCNO>NCT00460603</DOCNO>
	<brief_summary>To determine safety efficacy AG-013736 combination standard care medication patient first line metastatic colorectal cancer .</brief_summary>
	<brief_title>Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>( Phase 1 ) Patients solid/GI tumor 1 previous chemotherapy great 3 month prior enrollment ( Phase 2 ) Patients locally advanced metastatic colorectal cancer ( CRC ) previously untreated systemic therapy . Patients treat adjuvant chemotherapy ( radiation ) eligible last treatment &gt; 12 month prior enrollment , Patients must measurable disease RECIST history hypertension , must control medication . Prior system therapy advance CRC ( Ph 2 portion ) Prior treatment antiangiogenesis agent bevacizumab VEGF inhibitor . Prior irradiation great 25 % bone marrow ( whole pelvis = 25 % ) Prior radiation , major surgery , investigational agent within 4 week study entry except palliative radiotherapy nontarget , metastatic lesion . Minor surgery complete &gt; 2 week enrollment fully recovered procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>GI neoplasm ( phase 1 )</keyword>
</DOC>